A human study to evaluate safety and effective dose of Morus alba twig extract on postprandial glucose level in healthy subjects
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0001434
- Lead Sponsor
- Ewha Womans University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 24
1) Age: 20 years = Age < 40 years
2) FBG (Fasting Blood Glucose): < 126mg/dL
1) Continuous consumption of drug that affect glucose metabolism, inflammation, antioxidative capacity and lipid metabolism or dietary supplement or oriental medicine or within 4 weeks before the first visit
2) Consumption of anticoagulant within 4 weeks before the first visit
3) BMI=18.5 or BMI=30
4) Following diseases :
? Diagnosis of diabetes or fasting blood glucose = 126mg/dL at screening
? Liver dysfunction (AST, ALT level elevations more than 2.5 times the upper limit of normal)
? Renal dysfunction (serum creatinine = 1.4mg/dL)
? Cardiovascular diseases (hypertension (= 140/90 mmHg), stroke, etc.)
? Thyroid diseases, mental diseases such as depression, schizophrenia, alcoholism, drug addiction, wasting diseases such as malignant tumor etc., and severe muscular skeletal disease, asthma and allergic diseases, any condition that the principal investigator believes may put the subjects at undue risk
5) Chronic smoker (= 20 cigarettes / day)
6) Excessive exercise (= 10 hours / week)
7) Change of body weight more than 4 kg or weight control within 4 weeks before the first visit
8) Subjects with hypersensitivity to test materials
9) Participation in other human study within 4 weeks before the first visit
10) Pregnant or lactating women
11) Any condition that the principal investigator believes may put the subjects at undue risk
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood glucose
- Secondary Outcome Measures
Name Time Method